Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

@article{Grebely2017EfficacyOR,
  title={Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.},
  author={Jason Grebely and Olav Dalgard and Evan B Cunningham and Behzad Hajarizadeh and Graham R Foster and Philip Bruggmann and Bernadette Conway and Markus Backmund and Geert Robaeys and Tracy A. Swan and Jigar R Amin and Philippa S Marks and Sophie Quiene and Tanya Lynn Applegate and Martin D Weltman and Daniel Fern{\'a}ndez Shaw and Petra K. Staiger and Margaret E Hellard and Julie Bruneau and H{\aa}vard Midgard and Stefan A. Bourgeois and Cornelia Staehelin and Gregory J Dore},
  journal={The International journal on drug policy},
  year={2017},
  volume={47},
  pages={
          177-186
        }
}
BACKGROUND There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 infection among people with ongoing injecting drug use or receiving opioid substitution therapy (OST). A secondary aim was to identify predictors of HCV treatment response. METHODS ACTIVATE was a multicentre clinical trial recruited between 2012 and 2014. Participants with… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Recommendations for the management of hepatitis C virus infection among people who inject drugs

E A.GREBELYJ.
  • Int J Drug Policy
  • 2015
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…